hVIVO plc (AIM:HVO)
6.55
-0.19 (-2.82%)
Sep 25, 2026, 4:40 PM GMT
hVIVO Revenue
hVIVO had revenue of 16.27M GBP in the half year ending June 30, 2026, a decrease of -54.35%. This brings the company's revenue in the last twelve months to 38.85M, down -24.24% year-over-year. In the year 2025, hVIVO had annual revenue of 46.77M, down -25.43%.
Revenue (ttm)
38.85M
Revenue Growth
-24.24%
P/S Ratio
0.91
Revenue / Employee
132.07K
Employees
376
Market Cap
45.00M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 46.77M | -15.95M | -25.43% |
| Dec 31, 2024 | 62.73M | 6.68M | 11.92% |
| Dec 31, 2023 | 56.04M | 7.57M | 15.61% |
| Dec 31, 2022 | 48.48M | 11.61M | 31.50% |
| Dec 31, 2021 | 36.86M | 16.26M | 78.93% |
| Dec 31, 2020 | 20.60M | 17.23M | 510.97% |
| Dec 31, 2019 | 3.37M | -9.19M | -73.15% |
| Dec 31, 2018 | 12.56M | 1.68M | 15.45% |
| Dec 31, 2017 | 10.88M | -4.39M | -28.75% |
| Dec 31, 2016 | 15.27M | 7.55M | 97.85% |
| Dec 31, 2015 | 7.72M | -10.76M | -58.22% |
| Dec 31, 2014 | 18.47M | 16.78M | 993.17% |
| Dec 31, 2013 | 1.69M | -489.64K | -22.47% |
| Dec 31, 2012 | 2.18M | -689.38K | -24.03% |
| Dec 31, 2011 | 2.87M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 46.25B |
| GSK plc | 33.20B |
| Haleon | 11.15B |
| Smith & Nephew | 4.77B |
| BATM Advanced Communications | 78.81M |
| Shield Therapeutics | 44.19M |
| Abingdon Health | 9.57M |
| Creo Medical Group | 6.00M |
hVIVO News
- 4 days ago - Half Year 2026 hVIVO PLC Earnings Presentation Transcript - GuruFocus
- 10 days ago - hVIVO Earnings Call Transcript: H1 2026 - Transcripts
- 10 days ago - hVIVO Quarterly report: H1 2026 - Filings
- 10 days ago - hVIVO Slides: H1 2026 - Filings
- 2 months ago - hVIVO Earnings release: H1 2026 - Filings
- 3 months ago - hVIVO Transcript: CMD 2026 - Transcripts
- 3 months ago - hVIVO Slides: FY 2026 - Filings
- 3 months ago - Decoy Therapeutics Partners With HVIVO To Advance D-MAV Into Clinical Study; Stock Up - Nasdaq